How to Get GLP-1 Patients as a Psychiatrist

If you’re a psychiatrist wondering whether you can prescribe weight loss medication—or whether you should—the short answer is yes. And the timing couldn’t be better.

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide have created a seismic shift in obesity treatment. By 2025, an estimated 6% of Americans—roughly 20 million people—were actively taking GLP-1 drugs, a nearly 600% increase in weight-loss usage over six years. This isn’t a fad. It’s a fundamental change in how we treat obesity, and psychiatrists are uniquely positioned to capitalize on it.

Here’s why: You already understand behavior change. You manage chronic conditions. You prescribe medications that often cause weight gain. And many of your patients are desperately seeking solutions for obesity—whether it’s antipsychotic-induced weight gain, binge eating disorder, or the metabolic syndrome that shadows depression and anxiety.

The question isn’t whether psychiatrists can prescribe weight loss medication. It’s whether you’re ready to meet the overwhelming demand—and do it in a way that’s compliant, scalable, and doesn’t burn you out.

Why Psychiatrists Are Already Prescribing GLP-1s

By late 2023, surveys of major psychiatric departments found that nearly half of psychiatrists were already prescribing or recommending Ozempic or similar weight-loss drugs. This isn’t surprising. Psychiatrists regularly confront medication-induced weight gain—a side effect that can derail treatment adherence and worsen patients’ mental health.

But the opportunity extends far beyond your existing caseload. The obesity epidemic affects 75% of Americans, and there’s a massive gap between patient demand and provider supply. Traditional obesity medicine specialists are overwhelmed. Primary care doctors lack the bandwidth for the intensive monitoring GLP-1 therapy requires. This creates an opening for psychiatrists who understand the psychological dimensions of weight loss.

Unlike other prescribers, you bring expertise in:

• Behavioral change psychology – the foundation of sustainable weight loss
• Mental health monitoring – critical given early (now-dismissed) concerns about mood effects and suicidal ideation with GLP-1s
• Medication management in complex cases – balancing psych meds with metabolic treatments
• Telehealth fluency – most psychiatric practices already operate virtually, making the jump to telehealth weight management seamless

Your patients already trust you with their mental health. Extending that relationship to physical health—especially when the two are deeply intertwined—is a natural evolution.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Legal and Regulatory Reality: GLP-1 Prescribing via Telehealth

Federal Law Is On Your Side

GLP-1 medications are not controlled substances. This is crucial. The Ryan Haight Act—which restricts telehealth prescribing of controlled substances—doesn’t apply to semaglutide, tirzepatide, or other GLP-1 agonists. You can legally prescribe these medications via telehealth without an initial in-person visit, as long as you:

• Conduct a proper video evaluation (or audio-visual encounter meeting state standards)
• Establish a valid patient-provider relationship
• Document your clinical decision-making
• Follow the standard of care for obesity treatment

State Licensure Matters—A Lot

You must be licensed in the patient’s state. Period. A California psychiatrist can’t treat a Texas patient without a Texas license (or using Texas’s telehealth registration pathway). Some states participate in the Interstate Medical Licensure Compact (IMLC), which streamlines the multi-state licensing process for MDs and DOs. Texas, Pennsylvania, Illinois, and Florida are IMLC members. California and New York are not.

For Psychiatric Nurse Practitioners (PMHNPs), scope of practice varies significantly by state:

• California: PMHNPs currently need physician supervision/protocols unless they achieve the new AB 890 ‘104 NP’ independent status (which won’t be available until 2026 at the earliest, after completing 3 years as a supervised ‘103 NP’)

• Texas: Strict supervision required. PMHNPs must have a Prescriptive Authority Agreement with a Texas physician. No independent practice.

• Florida: PMHNPs require physician oversight. The 2020 ‘Autonomous APRN’ law only applies to primary care NPs (family medicine, general internal medicine, pediatrics)—not psychiatric specialists.

• New York: Experienced PMHNPs (3,600+ hours of practice) can operate independently without a collaborative physician agreement. This makes NY one of the most PMHNP-friendly markets.

• Pennsylvania: Full physician collaboration required. No independent NP practice exists. Bills to change this have stalled repeatedly.

• Illinois: PMHNPs can achieve Full Practice Authority (FPA) after 4,000 hours of clinical practice plus 250 hours of additional education. Once FPA-certified, they can prescribe independently—including GLP-1s.

Telehealth-Specific State Rules

Most states allow telehealth establishment of the patient-provider relationship for non-controlled substances. Key considerations:

• California requires documented patient consent for telehealth services
• Texas allows audio-only for mental health services but generally requires video for medical evaluations (though GLP-1 management arguably fits psychiatric scope)
• Florida offers an Out-of-State Telehealth Provider Registration for physicians, allowing you to treat Florida patients without full licensure (though you still need a license in your home state). GLP-1s are fair game under this registration since they’re non-controlled.
• New York and Pennsylvania have strong telehealth parity laws requiring insurers to cover telehealth equivalently to in-person care

No state specifically prohibits GLP-1 prescribing via telehealth. The main compliance risk is failing to meet your state’s general telemedicine standards—inadequate evaluation, poor documentation, or practicing without proper licensure.

The Economics: Cash-Pay vs. Insurance

Here’s the uncomfortable truth: most patients pay cash for GLP-1 weight-loss services, and that’s actually an advantage for providers.

Why Insurance Is Complicated

While most insurers cover GLP-1 drugs for diabetes, coverage for obesity remains limited. As of mid-2024, only 13 state Medicaid programs (including California, Pennsylvania, and Illinois) covered GLP-1s for weight loss. Many private plans exclude them entirely. Medicare historically didn’t cover weight-loss drugs at all, though late-2025 announcements suggest pilot programs may change this.

Even when medication coverage exists, insurers often impose:

• Prior authorization requirements (time-consuming)
• BMI thresholds higher than FDA approval criteria
• Mandatory lifestyle program participation
• Step therapy (requiring failure on other treatments first)

Billing insurance for visits is feasible—you can use standard E/M codes for obesity counseling or Medicare’s G0447 (behavioral counseling for obesity). But prior authorizations for the medications themselves often fall to the patient and pharmacy, not the provider.

The Cash-Pay Model Works

Many successful GLP-1 telehealth practices operate entirely cash-pay:

• Monthly subscription model: Patients pay a flat fee (e.g., $200-400/month) covering consultations, medication management, and sometimes compounded semaglutide from partner pharmacies
• Per-visit model: Initial consult ($150-300), follow-ups ($75-150), medication separate
• Hybrid: Cash for initial intensive phase, transition to insurance billing for maintenance

Patients are often willing to pay because:

1. GLP-1s deliver dramatic, measurable results
2. Alternatives (bariatric surgery, endless failed diets) are expensive or emotionally costly
3. The total monthly cost (consult + medication) can be $300-600—less than many patients spend on ineffective supplements, meal plans, or gym memberships

Transparency is critical. Set clear expectations about costs upfront. If you’re using compounded semaglutide to lower medication costs, explain that it’s not FDA-approved but legally prescribed and often pharmacy-compounded from FDA-approved ingredients. If a patient needs brand-name Wegovy at $1,300+/month, they deserve to know before starting.

The cash-pay model also simplifies your operations: no insurance credentialing, no claim denials, no administrative bloat. You control pricing, and patients who can’t afford it will self-select out—freeing you to focus on motivated, committed clients.

How to Actually Get GLP-1 Patients as a Psychiatrist

Patient acquisition isn’t about spending thousands on marketing. It’s about recognizing the demand that already exists and positioning yourself to capture it.

Start Internal: Your Existing Patients

Many of your current psychiatric patients are ideal GLP-1 candidates. They may have:

• Weight gain from antipsychotics, mood stabilizers, or antidepressants
• BMI ≥30 (or ≥27 with comorbidities like hypertension, prediabetes)
• Binge eating disorder or emotional overeating
• Depression or anxiety worsened by poor body image

Introduce weight-loss medication during medication reviews. Frame it as integrated care—addressing both mental and metabolic health. Many patients will be relieved that you’re willing to treat the ‘whole person’ rather than siloing their care.

Conversion insight: You don’t need new patient acquisition when 20-30% of your existing caseload might benefit from GLP-1 therapy. That’s immediate revenue with zero marketing spend.

External Marketing: Telehealth Platforms and Direct Outreach

If you want volume beyond your current practice:

1. Join a Telehealth Platform (Like Klarity)

Platforms like Klarity Health handle patient acquisition for you. They invest heavily in advertising, SEO, and patient matching. You join their provider network and see pre-qualified patients who’ve already expressed interest in GLP-1 therapy.

The economics are straightforward: Instead of gambling $3,000-5,000/month on Google Ads, SEO agencies, or directory subscriptions with uncertain ROI, you pay only when a qualified patient books with you. Klarity uses a pay-per-appointment model—a standard listing fee per new patient lead. You get:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate EMR or video platform costs)
• Both insurance and cash-pay patient flow
• Schedule control—you decide how many patients you want to see

No upfront marketing spend. No wasted ad dollars on clicks that don’t convert. Guaranteed ROI.

2. DIY Marketing (If You Have Budget and Patience)

Building your own patient pipeline through SEO and Google Ads is possible, but let’s be realistic about the costs:

• SEO: Takes 6-12 months of consistent investment before generating meaningful patient flow. You’ll need a professional website, regular blog content, local SEO optimization, and backlink building. Budget $2,000-4,000/month for a competent agency. Most solo providers don’t have the expertise or patience.

• Google Ads: Mental health and weight-loss keywords are expensive ($15-40+ per click). Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in ad spend testing, optimization, no-shows from cold leads, and months of campaign refinement.

• Directory Listings: Psychology Today, Zocdoc, and similar platforms charge monthly fees ($30-300/month) AND you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+), and while the per-booking model is similar to Klarity, you’re handling all the patient communication, qualification, and scheduling yourself.

Total reality check: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you account for ALL costs—agency/consultant fees, ad spend, staff time to handle and qualify leads, no-show rates, and failed campaigns.

Klarity removes that risk entirely. You pay only when a patient shows up.

3. Referral Relationships

Let local primary care physicians, endocrinologists, therapists, and dietitians know you offer GLP-1 management. Emphasize your psychiatric expertise—you can address the psychological barriers to weight loss that sabotage most patients. Send brief introduction emails or arrange coffee meetings. Offer to send updates on shared patients.

Referrals are often high-quality (warm leads) and cost nothing but relationship-building time.

Marketing Positioning: Own Your Niche

Differentiate yourself from generic weight-loss clinics by emphasizing:

• ‘Psychiatrist-led weight management integrating mental and metabolic health’
• ‘GLP-1 therapy with psychological support for lasting results’
• ‘Treating medication-induced weight gain and obesity in mental health patients’

This messaging attracts patients who understand they need more than a prescription—they need a provider who gets the mind-body connection.

Scaling GLP-1 Practice Without Burning Out

Here’s the trap: GLP-1 demand is so high that you could easily drown in appointments. Tens of thousands of new patients start these medications every week. Without deliberate workflow design, you’ll hit capacity fast and burn out.

Workflow Optimization

Standardize intake: Use digital forms to collect comprehensive history before the first visit—weight history, diet, medical conditions, mental health screening, contraindications. This saves 15-20 minutes per appointment and ensures you don’t miss critical information.

Create protocols: Develop standardized order sets for baseline labs (A1c, TSH, liver panel) and dose titration schedules. Template your documentation for common scenarios (starting therapy, managing nausea, dose increases). This consistency speeds up charting and reduces decision fatigue.

Use checklists: A one-page ‘GLP-1 Initial Consult Checklist’ ensures you cover nutrition, exercise, goal-setting, medication teaching, and mental health screening every time—without relying on memory.

Delegate Non-Specialist Tasks

You don’t need to do everything. Scaling requires a team:

• Medical assistants or RNs: Gather weights, blood pressure, symptom questionnaires ahead of visits. Handle routine patient questions via portal messaging (‘Is nausea normal on this dose?’).

• Health coaches or dietitians: Conduct 2-week or monthly check-ins between your appointments. Lead group telehealth sessions for lifestyle counseling, reducing repetitive one-on-one work.

• Administrative staff: Schedule appointments, handle billing, manage prior authorizations (if you’re billing insurance).

By delegating these tasks, you focus on medication decisions and complex counseling—the high-value work only you can do.

Follow-Up Cadence and Automation

GLP-1 patients typically need monthly follow-ups during the first 3-6 months (dose titration, side effect management). After stabilization, visits can stretch to every 2-3 months.

Use technology to scale:

• Automated appointment reminders reduce no-shows
• Asynchronous check-ins (patients report weight and symptoms via app or portal) let you monitor between visits without scheduling time
• Template responses for common questions (nausea management, injection technique) save time
• Remote monitoring tools (connected scales, apps that graph weight trends) give you at-a-glance progress views

A well-designed telehealth platform (like Klarity’s built-in infrastructure) handles much of this automatically.

Set Boundaries to Prevent Burnout

Don’t try to absorb infinite demand. Instead:

• Cap daily GLP-1 appointments: Start with 5-10 per week, scale gradually as you refine workflows
• Block admin time: Schedule non-clinical hours for charting, reviewing labs, and planning
• Define availability hours: Set firm boundaries for patient messaging (e.g., ‘I respond to messages 9 AM – 5 PM weekdays’)
• Take vacations: Telehealth flexibility is great, but don’t let it blur work-life boundaries

Research shows that greater schedule control and virtual practice options significantly reduce provider burnout. Use that flexibility strategically.

Consider Team-Based Models

If demand exceeds your capacity, hire or collaborate with other providers:

• Supervise PMHNPs (in states allowing it) to handle routine follow-ups
• Partner with another psychiatrist to share on-call coverage
• Join or create a group practice where you focus on complex cases and initial evaluations while mid-levels handle maintenance

This scales impact without scaling your personal workload linearly.

What About the Mental Health Side Effects?

In late 2023, reports surfaced about rare suicidal ideation possibly linked to GLP-1s, triggering investigations. By early 2026, the FDA reviewed data and found no clear causal link, even directing removal of suicide warnings from GLP-1 labels.

Still, as a psychiatrist, you should monitor for mood changes during treatment. This is actually a competitive advantage—you’re trained to spot subtle psychiatric symptoms that other providers might miss. Ask about mood, anxiety, and suicidal thoughts at every follow-up. If a patient reports worsening depression, you can adjust their psychiatric medications concurrently or pause GLP-1 therapy if needed.

Some early research even suggests GLP-1s might independently improve certain psychiatric symptoms (potentially reducing symptoms in depression and bipolar disorder). The mechanism isn’t fully understood, but many psychiatrists report subjective improvements in their patients’ mood as weight loss progresses—likely due to improved self-image, better sleep, and reduced inflammation.

Your psychiatric expertise isn’t a liability here. It’s a differentiator.

Compliance Checklist: Covering Your Bases

To prescribe GLP-1s safely and legally via telehealth:

Licensure:

• ✅ Hold an active medical license in every state where your patients are located
• ✅ If you’re a PMHNP, verify your state allows independent prescribing or have a collaborative agreement in place
• ✅ Consider IMLC membership if you want to practice in multiple compact states (speeds up licensing)

Standard of Care:

• ✅ Conduct a thorough telehealth evaluation (medical history, weight history, BMI calculation, contraindication screening)
• ✅ Obtain informed consent for telehealth and for GLP-1 therapy (document this)
• ✅ Order baseline labs before starting therapy
• ✅ Educate patients about side effects, injection technique, and lifestyle modifications
• ✅ Schedule regular follow-ups (at least monthly during titration)

Documentation:

• ✅ Document clinical justification (BMI, comorbidities) for prescribing
• ✅ Note any off-label use and patient understanding
• ✅ Record weight, vital signs, and symptom checks at every visit
• ✅ Track medication dose changes and patient response

Pharmacy and Medication Safety:

• ✅ Prescribe FDA-approved medications when possible (Wegovy, Saxenda) or use reputable compounding pharmacies
• ✅ Avoid unregulated compounders (FDA has issued warnings about quality issues)
• ✅ Stay updated on drug shortages (GLP-1 supply issues have occurred intermittently)

Malpractice Insurance:

• ✅ Notify your malpractice carrier that you’re offering weight-loss services
• ✅ Confirm coverage extends to telehealth in all states where you practice

The Bottom Line: Should You Do This?

If you’re a psychiatrist looking to:

• Diversify your practice and income
• Meet overwhelming patient demand
• Integrate mental and metabolic health
• Build a scalable telehealth service

…then prescribing GLP-1 weight-loss medications is a massive opportunity. The market is exploding. Patient demand far exceeds provider supply. Your psychiatric training positions you uniquely to deliver holistic, sustainable care.

But don’t wing it. Get licensed properly. Build efficient workflows. Set boundaries. And consider partnering with a platform like Klarity that handles patient acquisition, telehealth infrastructure, and credentialing—so you can focus on what you do best: treating patients.

The 20 million Americans taking GLP-1s today will be 30 million tomorrow. The question is whether you’ll be there to meet them—on your terms, without burning out.

Frequently Asked Questions

Can psychiatrists legally prescribe weight loss medication like Ozempic or Wegovy?

Yes. Psychiatrists (MD/DO) can prescribe GLP-1 medications in any state where they hold a medical license. GLP-1s are not controlled substances, so federal restrictions like the Ryan Haight Act don’t apply. The key requirement is being licensed in the patient’s state and following that state’s standard of care for obesity treatment.

Do I need a special certification to prescribe GLP-1s?

No special certification is required. However, psychiatrists should familiarize themselves with obesity medicine best practices—baseline labs, contraindication screening, dose titration protocols, and lifestyle counseling. Many providers pursue CME in obesity medicine to increase confidence and competence, but it’s not legally required.

Can psychiatric nurse practitioners (PMHNPs) prescribe weight loss medication?

It depends on the state. In states with full NP practice authority (like New York for experienced NPs, or Illinois for FPA-certified NPs), PMHNPs can prescribe GLP-1s independently. In states requiring physician collaboration (Texas, Pennsylvania, Florida, California currently), PMHNPs must have a supervising physician agreement to prescribe these medications.

Can I prescribe GLP-1s via telehealth without seeing the patient in person?

Yes. Since GLP-1 medications are not controlled substances, you can establish a patient-provider relationship via telehealth (typically synchronous video) and prescribe without an initial in-person visit. You must be licensed in the patient’s state, conduct an adequate evaluation, document appropriately, and follow state telehealth standards.

Is it better to run a cash-pay or insurance-based GLP-1 practice?

Cash-pay is often simpler and more profitable. Most insurers don’t cover GLP-1s for obesity, so patients pay out-of-pocket for medications anyway. Cash-pay for visits avoids prior authorizations and claim denials. However, accepting insurance can widen your patient base—especially in states where Medicaid covers GLP-1s (California, Pennsylvania, Illinois as of 2024). Many providers use a hybrid model: cash for initial intensive consults, insurance for follow-ups when coverage exists.

How much can I realistically earn from adding GLP-1 services?

Revenue depends on patient volume and pricing model. In a cash-pay model, initial consults might generate $150-300 and follow-ups $75-150. If you see 20 GLP-1 patients/month with monthly follow-ups after initial consult, that’s roughly $4,000-6,000/month in additional revenue—more if you use subscription models ($200-400/patient/month). Joining a platform like Klarity with built-in patient flow can accelerate volume without marketing spend.

What are the most common side effects I’ll need to manage?

GI side effects dominate: nausea, vomiting, diarrhea, constipation. These are usually dose-dependent and improve with slower titration or supportive care. Rare but serious risks include pancreatitis, gallbladder issues, and thyroid concerns (contraindicated in patients with medullary thyroid carcinoma history). Psychiatrically, monitor for mood changes—though the FDA found no causal link to suicidal ideation, vigilance is warranted given your expertise.

How do I avoid burnout if demand is so high?

Scale thoughtfully. Start by capping weekly GLP-1 appointments (e.g., 5-10/week), use standardized workflows and templates, delegate non-specialist tasks to staff, leverage telehealth automation (asynchronous check-ins, remote monitoring), and set firm availability boundaries. Consider team-based models (supervising NPs or partnering with other providers) to share the load. Platforms like Klarity also control patient flow—you decide how many appointments to accept.

Do I need malpractice insurance that covers weight-loss prescribing?

Most general malpractice policies cover prescribing within your scope of practice. Since obesity is a recognized medical condition and you’re a licensed physician, prescribing GLP-1s typically falls under standard coverage. However, notify your insurer that you’re offering weight-management services to confirm coverage—especially if you’re practicing in multiple states via telehealth.

What’s the fastest way to get GLP-1 patients?

The fastest, lowest-risk path is joining a telehealth platform like Klarity Health. They handle patient acquisition, credentialing, telehealth infrastructure, and billing. You pay only per appointment (no upfront marketing spend or monthly fees). Alternatively, start with your existing psychiatric patients who need weight management—immediate conversion with zero acquisition cost. DIY marketing (SEO, Google Ads) works but takes 6-12 months and $3,000-5,000/month in spend to generate consistent patient flow.

Ready to meet the GLP-1 demand without the marketing headaches? Join Klarity Health’s provider network and start seeing pre-qualified weight-loss patients this month. No upfront costs. No advertising gambles. Just patients ready to book—on your schedule. Learn more about joining Klarity →

Citations

1. Axios – ‘Just how many Americans are taking GLP-1s now’ (Fair Health data on usage), May 27, 2025. https://www.axios.com/2025/05/27/american-glp1-use-weight-loss-increasing

2. ConfectioneryNews – ‘GLP-1 drugs like Ozempic are reshaping health, diet and the food industry,’ October 20, 2025. https://www.confectionerynews.com/Article/2025/10/20/glp-1-drugs-like-ozempic-are-reshaping-health-diet-and-the-food-industry/

3. Time – ‘The Heavy Cost of Using Weight-Loss Drugs to Get Skinny,’ August 22, 2025. https://time.com/7311517/cost-weight-loss-drugs-skinny/

4. Axios – ‘America’s doctors need more obesity medicine training,’ May 28, 2024. https://www.axios.com/2024/05/28/us-doctors-obesity-health-care-training

5. Axios – ‘States slow to cover GLP-1s for weight loss,’ November 5, 2024. https://www.axios.com/2024/11/05/states-slow-to-cover-glp-1s-for-weight-loss

6. PharmaNewsIntelligence (via forum.schizophrenia.com) – ‘Psychiatrists Prescribe or Recommend Ozempic…,’ November 6, 2023. https://forum.schizophrenia.com/t/psychiatrists-recommend-ozempic/311318

7. California Board of Registered Nursing – AB 890 Implementation FAQ (updated November 2024). https://www.rn.ca.gov/practice/ab890

8. MedicalDirectorCo – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide,’ 2025. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

9. Wheel Health – ‘Florida Telehealth Regulations and Laws,’ 2022 (post-SB312). https://www.wheel.com/state-telehealth-regulations/florida

10. SingleAim Health – ‘Nurse Practitioner Collaborative Agreement Templates: 50-State Guide,’ 2023. https://www.singleaimhealth.com/news/nurse-practitioner-collaborative-agreement-templates-50-state-guide

11. Commonwealth of Pennsylvania – Press Release: ‘Shapiro Administration Expands Job Opportunities for Doctors, Nurses, Physical Therapists,’ June 23, 2025. https://www.pa.gov/agencies/dos/newsroom/shapiro-expands-job-opportunities-for-doctors-nurses-physical

12. American Association of Nurse Practitioners (AANP) – State Practice Environment: Illinois, 2023. https://www.aanp.org/advocacy/illinois

13. Rivkin Radler LLP – ‘New Law Allows Experienced NPs to Practice Independently in NY,’ April 2022. https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/

14. Florida Senate – Florida Statutes 464.0123 (Advanced Practice Registered Nurses), 2023. https://www.flsenate.gov/laws/statutes/2023/464.0123

15. CompHealth – ‘Interstate Medical Licensure Compact (IMLC) Guide,’ 2024. https://comphealth.com/resources/interstate-medical-licensure-compact

16. Metabolic Mind Podcast – ‘Psychiatrist Shares His Experience with GLP-1 Weight Loss Drugs with Dr. Rodrigo Mansuer,’ 2024. https://www.metabolicmind.org/resources/news-views/podcasts/metabolic-mind-podcast/psychiatrist-shares-his-experience-with-glp1-weight-loss-drugs-with-dr-rodrigo-mansuer/

17. Associated Press – ‘FDA says weight-loss drugs don’t increase suicidal thoughts,’ January 2026. https://apnews.com/article/08983718dddcc1634ad3ba6ff23663ba

18. TeleCareAware – ‘GLP-1 and Telehealth Industry Coverage,’ 2024. https://telecareaware.com/tag/glp-1/

19. Axios – ‘Medicare and Medicaid GLP-1 Coverage Announcements,’ August-November 2025. https://www.axios.com/2025/08/01/medicare-medicaid-glp1-coverage-ozempic and https://www.axios.com/2025/11/06/medicare-coverage-weight-loss-glp1-ozempic-trump

20. ScienceDirect – ‘Effects of flexible scheduling and virtual practice on physician burnout,’ Journal of Psychiatric Research, 2022. https://www.sciencedirect.com/science/article/abs/pii/S2211034822002206

Source:

• https://www.axios.com/2025/05/27/american-glp1-use-weight-loss-increasing#:~:text=More%20than%202,their%20original%20approved%20use
• https://www.confectionerynews.com/Article/2025/10/20/glp-1-drugs-like-ozempic-are-reshaping-health-diet-and-the-food-industry/#:~:text=GLP,real%20number%20according%20to%20Kim
• https://forum.schizophrenia.com/t/psychiatrists-recommend-ozempic/311318#:~:text=Drugs%20pharmanewsintel
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=equivalent%20to%20in,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,with%20chart%20review%2C%20plus%20meetings
• https://www.singleaimhealth.com/news/nurse-practitioner-collaborative-agreement-templates-50-state-guide#:~:text=In%20Pennsylvania%2C%20Certified%20Registered%20Nurse,the%20CRNP%20and%20the%20collaborating
• https://www.wheel.com/state-telehealth-regulations/florida#:~:text=Are%20There%20Online%20Prescription%20Restrictions,for%20Telehealth%20in%20Florida
• https://time.com/7311517/cost-weight-loss-drugs-skinny/#:~:text=most%20insurances%20cover%20the%20medication,A%20recent%20Annals%20of%20Internal
• https://www.axios.com/2024/11/05/states-slow-to-cover-glp-1s-for-weight-loss#:~:text=What%20they%20found%3A%20In%20all%2C,a%20primary%20concern%2C%20KFF%20found
• https://time.com/7311517/cost-weight-loss-drugs-skinny/#:~:text=But%20these%20medications%20were%20originally,diabetes%2C%20weight%20loss%20treatment%20is